Skip to main content

Table 1 Patients characteristics

From: Pretreatment peripheral neutrophils, lymphocytes and monocytes predict long-term survival in hepatocellular carcinoma

Variables

No.(%)/median (range)

Age

60 (27–88)

Gender

 Male

1335 (79.4%)

 Female

346 (20.6%)

Etiology

 HBV

1039 (61.8%)

 HCV

279 (16.6%)

 Alcohol

184 (11.0%)

 Others

179 (10.6%)

Cirrhosis

1431 (85.1%)

Tumor characteristics

 Number (single)

1151 (68.5%)

 Size, cm

3.2 (1–20)

 Vascular invasion

313 (18.6%)

 Extrahepatic metastases

136 (8.1%)

BCLC stage

 Stage A

764 (45.4%)

 Stage B

495 (29.5%)

 Stage C

363 (21.6%)

 Stage D

59 (3.5%)

Child-Pugh

 Child-Pugh A

1454 (86.5%)

 Child-Pugh B

202 (12.0%)

 Child-Pugh C

25 (1.5%)

Peripheral cell counts, 106/L

 Neutrophil

3100 (630–17,500)

 Lymphocyte

1640 (270–7250)

 Monocyte

470 (60–2030)

 Platelet

145,000 (17,000–685,000)

Primary treatment

 Resection

407 (24.2%)

 Liver transplantation

51 (3.0%)

 RFA

138 (8.2%)

 TACE

710 (42.2%)

 Sorafenib

179 (10.7%)

 Others

14 (0.8%)

 Radiotherapy

12 (0.7%)

 Supportive care

171 (10.2%)

  1. Abbreviations: BCLC Barcelona clinic liver cancer; HBV Hepatitis B virus; HCV Hepatitis C virus; RFA Radiofrequency ablation; TACE Transarterial checmoembolization